7,17-diHDPAn-3 slightly changes the metabolism of the erythroid progenitor. (A) Partial least square-discriminant analysis shows clustering between controls at 36 hpf and 7,17-diHDPAn-3 treatment. (B) Volcano plots indicate log2 fold change (x-axis) and –log₁₀ of related P values, highlighting significant AC (14:0), nicotinamide, and citrate decreases in the 7,17-diHDPAn-3–treated group. (C) Heat map of the top 25 most significant metabolites (t test) reveals differences (primarily decreases) in carboxylic acid metabolism, free FAs, and ACs after 7,17-diHDPAn-3 treatment. (D) Highlights of metabolic differences between controls at 36 hpf and 7,17-diHDPAn-3 treatment in glycolysis, glutaminolysis, and the Krebs cycle. Global metabolomics analysis shows different metabolic patterns (primarily in carboxylic acid, free FA, and AC metabolism) between controls at 36 hpf and 7,17-diHDPAn-3 treatment. CoA, coenzyme A; ctrl, control; FC, fold change; PC1, principal component 1; PLS-DA, partial least square-discriminant analysis.